Jfl Life Sciences shareholders and shareholding pattern
NSE: JFLLIFEPharmaceuticals & Biotechnology
Jfl Life Sciences Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Sep 2022 · Issue price ₹61
Last close ₹10.00down ₹0.25 (2.44%)
Share price at the NSE close on 28 Oct 2026. Previous close ₹10.25.
28 Oct: open ₹10.00, high ₹10.00, low ₹10.00
52-week range of traded prices to 28 Oct 2026
₹8.55Low, 30 Mar 2026₹15.40High, 24 Dec 2025
- Next results date: the board meets on 2 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹33 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 4.87
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.72
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 15.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.47
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 6,000100.0% delivered
Jfl Life Sciences' shareholding pattern for Sep 2026, filed on 2 Oct 2026, with every filing from Sep 2022: who owns its shares by group, its promoters by name and its public holders of 1% or more.
Who owns Jfl Life Sciences, filing by filing
Per cent of the company's shares.
Sep 2026 filing
- Promoters67.47%
- Individuals and others32.53%
Shareholding pattern, per cent
- Promoters
- Individuals and others
| Per cent | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | |
| Indian promoters | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% |
| Public. Every shareholder outside the promoter group, the employee trusts and the shares held against depositary receipts, as the filing totals them. Public in the glossary | 32.53% | 32.53% | 32.54% | 32.53% | 32.53% | 32.53% | 32.53% | 32.53% | 32.53% | 32.53% | 32.53% | 32.53% | 32.53% |
| Shares in issue | 1,09,98,441 | 1,09,98,441 | 1,09,98,441 | 1,09,98,441 | 1,09,98,441 | 1,09,98,441 | 1,09,98,441 | 3,29,95,323 | 3,29,95,323 | 3,29,95,323 | 3,29,95,323 | 3,29,95,323 | 3,29,95,323 |
| Shares locked inShares locked in. Shares the filing reports as barred from sale until a set day, such as promoters' shares after a public issue or shares allotted to an investor directly. Shares locked in in the glossary | 80,20,441 | 80,20,441 | 80,20,441 | 21,99,689 | 21,99,689 | 21,99,689 | 21,99,689 | 65,99,067 | – | – | – | – | – |
| Promoters' shares locked in | 74,20,441 | 74,20,441 | 74,20,441 | 21,99,689 | 21,99,689 | 21,99,689 | 21,99,689 | 65,99,067 | – | – | – | – | – |
A dash is a line the filing did not state.
Jfl Life Sciences promoters
Promoters are the founders, families and companies that control the company, as its filings name them. Every member of the promoter group holding shares in the filing for Sep 2026; the largest is SMIRAL ASHWINKUMAR PATEL, 44.33%.
| Holder | ||
|---|---|---|
| SMIRAL ASHWINKUMAR PATELIndividuals and Hindu undivided families | 44.33% | 1,46,25,630 |
| TEJAL SMIRAL PATELIndividuals and Hindu undivided families | 16.58% | 54,71,154 |
| SMIRAL ASHWINKUMAR PATEL HUFIndividuals and Hindu undivided families | 3.98% | 13,14,222 |
| ASHWINBHAI JIVRAMBHAI PATELIndividuals and Hindu undivided families | 0.89% | 2,93,007 |
| PATEL DAKSHABENIndividuals and Hindu undivided families | 0.37% | 1,22,070 |
| RUPESH KIRTIBHAI PATELIndividuals and Hindu undivided families | 0.34% | 1,10,760 |
| ASHOKKUMAR PARSHOTTAMDAS PATELIndividuals and Hindu undivided families | 0.27% | 89,700 |
| USHABEN ASHOKKUMAR PATELIndividuals and Hindu undivided families | 0.21% | 70,200 |
| ARTIBEN MANISHKUMAR PATELIndividuals and Hindu undivided families | 0.20% | 67,470 |
| SHOBHNABEN KIRTIKUMAR PATELIndividuals and Hindu undivided families | 0.18% | 58,110 |
| KIRTIKUMAR PARSHOTTAMBHAI PATELIndividuals and Hindu undivided families | 0.12% | 39,000 |
No promoter shares are reported as pledged.
Largest public holders of Jfl Life Sciences, filing by filing
Per cent, on the same shares as the split above.
| Holder | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRATIK RAJENDRABHAI GANDHIResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | – | – | 1.22% | – | 1.22% | 1.22% | 1.22% |
| PRATIK RAJENDRA GANDHIResident individuals, over ₹2 lakh at face value | – | – | – | – | 1.82% | – | – | 1.22% | – | 1.22% | – | – | – |
| ANUJ GUPTAResident individuals, over ₹2 lakh at face value | – | – | – | – | 1.15% | – | – | – | – | – | – | – | – |
| ECONO BROKING PRIVATE LIMITEDOther non-institutions | 1.31% | – | – | – | – | – | – | – | – | – | – | – | – |
A filing names every holder above one per cent, in the company's own words: an insurer's holding can carry one of its funds' names. A dash is a filing that did not name the holder, which includes holding under one per cent.